Literature DB >> 25018058

XRCC1 Arg194Trp and Arg399Gln polymorphisms and arsenic methylation capacity are associated with urothelial carcinoma.

Chien-I Chiang1, Ya-Li Huang2, Wei-Jen Chen1, Horng-Sheng Shiue3, Chao-Yuan Huang4, Yeong-Shiau Pu4, Ying-Chin Lin5, Yu-Mei Hsueh6.   

Abstract

The association between DNA repair gene polymorphisms and bladder cancer has been widely studied. However, few studies have examined the correlation between urothelial carcinoma (UC) and arsenic or its metabolites. The aim of this study was to examine the association between polymorphisms of the DNA repair genes, XRCC1 Arg194Trp, XRCC1 Arg399Gln, XRCC3 Thr241Met, and XPD Lys751Gln, with urinary arsenic profiles and UC. To this end, we conducted a hospital-based case-control study with 324 UC patients and 647 age- and gender-matched non-cancer controls. Genomic DNA was used to examine the genotype of XRCC1 Arg194Trp, XRCC1 Arg399Gln, XRCC3 Thr241Met, and XPD Lys751Gln by PCR-restriction fragment length polymorphism analysis (PCR-RFLP). Urinary arsenic profiles were measured by high performance liquid chromatography (HPLC) linked with hydride generator and atomic absorption spectrometry. The XRCC1 399 Gln/Gln and 194 Arg/Trp and Trp/Trp genotypes were significantly related to UC, and the odds ratio (OR) and 95% confidence interval (95%CI) were 1.68 (1.03-2.75) and 0.66 (0.48-0.90), respectively. Participants with higher total urinary arsenic levels, a higher percentage of inorganic arsenic (InAs%) and a lower percentage of dimethylarsinic acid (DMA%) had a higher OR of UC. Participants carrying XRCC1 risk diplotypes G-C/G-C, A-C/A-C, and A-T/G-T, and who had higher total arsenic levels, higher InAs%, or lower DMA% compared to those with other XRCC1 diplotypes had a higher OR of UC. Our results suggest that the XRCC1 399 Gln/Gln and 194 Arg/Arg DNA repair genes play an important role in poor arsenic methylation capacity, thereby increasing the risk of UC in non-obvious arsenic exposure areas.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Arsenic; Arsenic methylation capacity; Polymorphism; Urothelial carcinoma; XRCC1

Mesh:

Substances:

Year:  2014        PMID: 25018058     DOI: 10.1016/j.taap.2014.06.027

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  6 in total

Review 1.  Individual susceptibility to arsenic-induced diseases: the role of host genetics, nutritional status, and the gut microbiome.

Authors:  Liang Chi; Bei Gao; Pengcheng Tu; Chih-Wei Liu; Jingchuan Xue; Yunjia Lai; Hongyu Ru; Kun Lu
Journal:  Mamm Genome       Date:  2018-02-10       Impact factor: 2.957

2.  XRCC1 Polymorphisms and Urinary 8-Hydroxydeoxyguanine Levels Are Associated with Urothelial Carcinoma.

Authors:  Chien-I Chiang; Ya-Li Huang; Chao-Yuan Huang; Horng-Sheng Shiue; Wei-Jen Chen; Yeong-Shiau Pu; Ying-Chin Lin; Yu-Mei Hsueh
Journal:  PLoS One       Date:  2015-05-04       Impact factor: 3.240

3.  Correlation between XRCC1 Arg399Gln genetic polymorphisms and susceptibility to bladder cancer: a meta-analysis.

Authors:  Nannan Liu; Xiawei Fei; Yi Shen; Weifeng Shi; Jinhong Ma
Journal:  Onco Targets Ther       Date:  2016-01-28       Impact factor: 4.147

4.  Upregulation of glycolysis and oxidative phosphorylation in benzo[α]pyrene and arsenic-induced rat lung epithelial transformed cells.

Authors:  Huachen Chen; Lai-Sheung Lee; Guanwu Li; Sai-Wah Tsao; Jen-Fu Chiu
Journal:  Oncotarget       Date:  2016-06-28

5.  Association of nineteen polymorphisms from seven DNA repair genes and the risk for bladder cancer in Gansu province of China.

Authors:  Gongjian Zhu; Haixiang Su; Lingeng Lu; Hongyun Guo; Zhaohui Chen; Zhen Sun; Ruixia Song; Xiaomin Wang; Haining Li; Zhiping Wang
Journal:  Oncotarget       Date:  2016-05-24

Review 6.  The Association of Arsenic Metabolism with Cancer, Cardiovascular Disease, and Diabetes: A Systematic Review of the Epidemiological Evidence.

Authors:  Chin-Chi Kuo; Katherine A Moon; Shu-Li Wang; Ellen Silbergeld; Ana Navas-Acien
Journal:  Environ Health Perspect       Date:  2017-08-01       Impact factor: 9.031

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.